Development of a Plasmodium berghei transgenic parasite expressing the full-length Plasmodium vivax circumsporozoite VK247 protein for testing vaccine efficacy in a murine model.

Genetic diversity of Plasmodium vivax metacaspase 1 and Plasmodium vivax multi-drug resistance 1 genes of field isolates from Mauritania, Sudan and Oman. Malar J (2017) 0.75

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med (2011) 10.79

Estimating the global clinical burden of Plasmodium falciparum malaria in 2007. PLoS Med (2010) 7.22

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med (2012) 6.64

The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis (2010) 6.23

Circumsporozoite protein heterogeneity in the human malaria parasite Plasmodium vivax. Science (1989) 2.59

Identification of Plasmodium vivax-like human malaria parasite. Lancet (1993) 2.37

The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion. J Exp Med (2005) 1.85

Why is Plasmodium vivax a neglected tropical disease? PLoS Negl Trop Dis (2011) 1.62

A new rodent model to assess blood stage immunity to the Plasmodium falciparum antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies. J Exp Med (2003) 1.61

Population structure analysis of Plasmodium vivax in areas of iran with different malaria endemicity. Am J Trop Med Hyg (2006) 1.46

An update on the search for a Plasmodium vivax vaccine. Trends Parasitol (2007) 1.41

Plasmodium vivax malaria vaccine development. Mol Immunol (2001) 1.36

Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine. PLoS One (2012) 1.35

Circumsporozoite genotyping of global isolates of Plasmodium vivax from dried blood specimens. J Clin Microbiol (1992) 1.33

Genetic diversity of Plasmodium vivax isolates from Azerbaijan. Malar J (2004) 1.20

Variants of the Plasmodium vivax circumsporozoite protein (VK210 and VK247) in Colombian isolates. Mem Inst Oswaldo Cruz (2001) 1.20

Widespread reactivity of human sera with a variant repeat of the circumsporozoite protein of Plasmodium vivax. Am J Trop Med Hyg (1990) 1.14

The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials. Vaccine (2006) 1.12

Roles of the amino terminal region and repeat region of the Plasmodium berghei circumsporozoite protein in parasite infectivity. PLoS One (2012) 1.03

Global occurrence of Plasmodium vivax-like human malaria parasite. J Infect Dis (1993) 1.01

Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25. Infect Immun (2008) 1.01

Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission. Vaccine (2010) 0.98

Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint. Clin Vaccine Immunol (2013) 0.98

Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites. Infect Immun (2013) 0.97

Functional immunogenicity of baculovirus expressing Pfs25, a human malaria transmission-blocking vaccine candidate antigen. Vaccine (2010) 0.97

Construction of transgenic Plasmodium berghei as a model for evaluation of blood-stage vaccine candidate of Plasmodium falciparum chimeric protein 2.9. PLoS One (2009) 0.95

Mutational analysis of the GPI-anchor addition sequence from the circumsporozoite protein of Plasmodium. Cell Microbiol (2005) 0.93

Development of a chimeric Plasmodium berghei strain expressing the repeat region of the P. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy. Infect Immun (2013) 0.93

A baculovirus dual expression system-based malaria vaccine induces strong protection against Plasmodium berghei sporozoite challenge in mice. Infect Immun (2009) 0.93

Species-specific regulation and switching of transcription between stage-specific ribosomal RNA genes in Plasmodium berghei. J Biol Chem (1997) 0.87

Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites. Infect Immun (2014) 0.85

Reduction of malaria transmission by transgenic mosquitoes expressing an antisporozoite antibody in their salivary glands. Insect Mol Biol (2012) 0.85

Improvement of the observational method for Plasmodium berghei oocysts in the midgut of mosquitoes. Parasit Vectors (2011) 0.81

Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein. PLoS One (2013) 0.81

Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites. Infect Immun (2014) 0.85

Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein. PLoS One (2013) 0.81